以岭药业(002603) - 2025年4月29日投资者关系活动记录表

Group 1: Product Development and Clinical Trials - The company plans to submit 1-2 new products for approval each year, with recent submissions including products for chronic cholecystitis and rheumatoid arthritis [2] - Currently, there are 6 products in clinical stages, with one in Phase III for treating children's colds and five in Phase II for various conditions [2][3] - The company has completed the registration of 536 products and has a 90% average registration rate across 14 provinces for formula granules [5] Group 2: Health Industry Progress - The company has developed a comprehensive health product system integrating traditional Chinese medicine with modern technology, focusing on health management and product development [4] - Key promoted products include health foods and functional beverages, with significant revenue growth expected in 2024 [4] Group 3: Sales Strategies and Market Expansion - The company is enhancing sales of its BaZi products through retail, e-commerce, and partnerships, aiming to build brand recognition and customer loyalty [6][7] - The company has seen rapid growth in BaZi product sales in Q1 2025, with strategies to improve customer adherence and long-term management [6][7] Group 4: International Market Development - The company aims to enhance the international influence of traditional Chinese medicine by promoting its unique theories and establishing academic collaborations globally [11][12] - It has established over 130 professional committees abroad and has received approvals for its patented traditional medicines in over 50 countries [12] Group 5: OTC Product Strategy - The company’s Lianhua Qingke product transitioned to OTC status in November 2023, which is expected to create new marketing opportunities and enhance sales through flexible promotion strategies [13]